STOCK TITAN

Harrow Health Inc - HROW STOCK NEWS

Welcome to our dedicated page for Harrow Health news (Ticker: HROW), a resource for investors and traders seeking the latest updates and insights on Harrow Health stock.

Harrow Health Inc (HROW) is a leading developer of ophthalmic pharmaceuticals and non-intravenous sedation therapies, addressing critical needs in eyecare and procedural medicine. This dedicated news hub provides investors and healthcare professionals with timely access to official announcements and objective updates about the company's progress.

Our curated collection features earnings reports, regulatory milestones, and product development updates, offering a comprehensive view of HROW's strategic direction. Users will find essential information on FDA approvals, clinical trial results, and partnership announcements that shape the company's position in the pharmaceutical sector.

Key content categories include financial disclosures, research breakthroughs, and manufacturing updates related to compounded medications and sedation therapeutics. All materials are sourced from verified channels to ensure accuracy and relevance for decision-makers.

Bookmark this page for streamlined access to HROW's latest developments. Check back regularly for authoritative updates on innovations in ocular surface disease treatments and non-IV sedation solutions that demonstrate the company's commitment to advancing patient care.

Rhea-AI Summary
Melt Pharmaceuticals enters exclusive development and license agreement with Catalent for MELT-300, a sublingual formulation for procedural sedation during cataract surgery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.2%
Tags
none
-
Rhea-AI Summary
Harrow announces record revenues of $33.5 million, a 44% increase YoY, and a net loss of ($4.2) million. Also reports record adjusted EBITDA of $11.0 million, a 144% increase YoY. Completed public offering of common stock for $69 million. Acquired commercial rights to several drugs. Expanded Oaktree Loan to $112.50 million. Positive financial performance and acquisitions may positively impact stock price.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.45%
Tags
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.94%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.84%
Tags
-
Rhea-AI Summary
Santen Pharmaceutical Co., Ltd. (Santen) has signed licensing agreements with Visiox Pharmaceuticals, Inc. and Harrow Health, Inc. for the out-licensing of OMLONTI® and the transfer of various eye drop products. This includes exclusive rights for product manufacturing, commercialization, and sales in the U.S. and Canada, with potential royalty payments for Santen.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.84%
Tags
none
Rhea-AI Summary
Harrow (Nasdaq: HROW) Acquires U.S. and Canadian Commercial Rights to FLAREX®, NATACYN®, TOBRADEX® ST, VERKAZIA®, ZERVIATE®, FRESHKOTE®, and Cationorm® PLUS from Santen Pharmaceutical Co., Ltd. The acquisition aims to enhance Harrow's position in the U.S. ophthalmic pharmaceutical market, broadening its branded portfolio and offering high utility and trusted products for ophthalmic surgical and dry eye symptoms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.84%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.84%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.84%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.84%
Tags
Harrow Health Inc

Nasdaq:HROW

HROW Rankings

HROW Stock Data

855.34M
30.01M
13.49%
59.11%
7.72%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
NASHVILLE